Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34 + precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition

Immunotherapy

Volumn 3, Issue 9, 2011, Pages 1051-1061

  Van Cruijsen, Hester ^a   Oosterhoff, Dinja ^a   Lindenberg, Jelle J ^a   Lougheed, Sinéad M ^a   Fehres, Cynthia ^a   Weijers, Karin ^a   Van Boerdonk, Robert ^a   Giaccone, Giuseppe ^a   Scheper, Rik J ^a   Hoekman, Klaas ^a   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

dendritic cell; glioma; IL 6; STAT3

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; CD34 ANTIBODY; CUCURBITACIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 2; JSI 124; RAF PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CULTURE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; LANGERHANS CELL; LYMPHOCYTE FUNCTION; LYMPHOID PROGENITOR CELL; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIGENS, CD34; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; GLIOBLASTOMA; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; LANGERHANS CELLS; STAT3 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 80053046377     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.107     Document Type: Article

References (40)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
2. Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. Brain 130(Pt 10), 2596-2606 (2007). (Pubitemid 47511715)
3. de Vleeschouwer S, Rapp M, Sorg RV et al. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 59(5), 988-999 (2006). (Pubitemid 44852063)
4. Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11(15), 5515-5525 (2005). (Pubitemid 41060828)
5. Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66(6), 3294-3302 (2006).
6. Iwamoto M, Shinohara H, Miyamoto A et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer 104(1), 92-97 (2003). (Pubitemid 36184151)
7. Inoshima N, Nakanishi Y, Minami T et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin. Cancer Res. 8(11), 3480-3486 (2002). (Pubitemid 35340725)
8. Ogden AT, Horgan D, Waziri A et al. Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery 59(4), 902-909 discussion 909-910 (2006).
9. Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin 6 and macrophage colony-stimulating factor. Blood 92(12), 4778-4791 (1998). (Pubitemid 29005881)
10. Bharadwaj U, Li M, Zhang R et al. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res. 67(11), 5479-5488 (2007). (Pubitemid 46997289)
11. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096-1103 (1996). (Pubitemid 26338628)
12. van Cruijsen H, van der Veldt AA, Vroling L et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 14(18), 5884-5892 (2008).
13. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6(5), 1755-1766 (2000). (Pubitemid 30305068)
14. Smithgall TE, Briggs SD, Schreiner S et al. Control of myeloid differentiation and survival by Stats. Oncogene 19(21), 2612-2618 (2000). (Pubitemid 30339217)
15. Nefedova Y, Huang M, Kusmartsev S et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172(1), 464-474 (2004). (Pubitemid 38020502)
16. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat 3 signaling in tumor cells. Nat. Med. 10(1), 48-54 (2004). (Pubitemid 38524698)
17. Valladeau J, Ravel O, Dezutter-Dambuyant C et al. Langerin, a novel C type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12(1), 71-81 (2000). (Pubitemid 30069216)
18. Romani N, Koide S, Crowley M et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J. Exp. Med. 169(3), 1169-1178 (1989). (Pubitemid 19085847)
19. Tateno H, Ohnishi K, Yabe R et al. Dual specificity of langerin to sulfated and mannosylated glycans via a single C type carbohydrate recognition domain. J. Biol. Chem. 285(9), 6390-6400 (2010).
20. Santegoets SJ, van den Eertwegh AJ, van de Loosdrecht AA et al. Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. J. Leukoc. Biol. 84(6), 1364-1373 (2008). (Pubitemid 352774471)
21. Santegoets SJ, Gibbs S, Kroeze K et al. Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions. J. Leukoc. Biol. 84(1), 143-151 (2008). (Pubitemid 351960289)
22. Santegoets SJ, Masterson AJ, van der Sluis PC et al. A CD34+ human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+ Langerhans cell precursor. J. Leukoc. Biol. 80(6), 1337-1344 (2006). (Pubitemid 44904972)
23. Santegoets SJ, Bontkes HJ, Stam AG et al. Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. J. Immunol. 180(7), 4540-4549 (2008).
24. Sombroek CC, Stam AG, Masterson AJ et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168(9), 4333-4343 (2002). (Pubitemid 34441333)
25. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004). (Pubitemid 39620069)
26. Park SJ, Nakagawa T, Kitamura H et al. IL 6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173(6), 3844-3854 (2004). (Pubitemid 39280747)
27. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7(1), 41-51 (2007). (Pubitemid 46020826)
28. de la Iglesia N, Konopka G, Lim KL et al. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J. Neurosci. 28(23), 5870-5878 (2008).
29. Su Y, Li G, Zhang X et al. JSI 124 inhibits glioblastoma multiforme cell proliferation through G2/M cell cycle arrest and apoptosis augment. Cancer Biol. Ther. 7(8), 1243-1249 (2008).
30. Fujita M, Zhu X, Sasaki K et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J. Immunol. 180(4), 2089-2098 (2008).
31. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110(9), 1911-1928 (2007). (Pubitemid 350036849)
32. Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin 6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 72(3), 424-430 (1997). (Pubitemid 27325869)
33. Cabillic F, Bouet-Toussaint F, Toutirais O et al. Interleukin 6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk. Clin. Exp. Immunol. 146(3), 518-523 (2006). (Pubitemid 44722172)
34. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin 6. Blood 100(1), 230-237 (2002). (Pubitemid 35177452)
35. Tchirkov A, Khalil T, Chautard E et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br. J. Cancer 96(3), 474-476 (2007). (Pubitemid 46215219)
36. Schreiber S, Kilgus O, Payer E et al. Cytokine pattern of Langerhans cells isolated from murine epidermal cell cultures. J. Immunol. 149(11), 3524-3534 (1992).
37. Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68(14), 5955-5964 (2008).
38. Tang J, Flomenberg P, Harshyne L et al. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin. Cancer Res. 11(14), 5292-5299 (2005). (Pubitemid 41003718)
39. De Vleeschouwer S, Fieuws S, Rutkowski S et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin. Cancer Res. 14(10), 3098-3104 (2008).
40. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N. Engl. J. Med. 359(5), 539-541 (2008).